Dana-Farber Wins Legal Dispute over PD-1/PD-L1 Patents; BMS Loses Exclusive License

May 25, 2019 | Federal Court, Patent Law, Ruling

Dana-Farber Cancer Institute filed a suit in the United States District Court District of Massachusetts. On May 17, the judge, Honorable Patti B. Saris, issued their legal conclusion in a Findings of Fact, Conclusions of Law and Order.  In 111 pages of fascinating nonfiction, the court rules Dana-Farber is entitled to intellectual property rights to six patents that claim methods of treating cancer by administering anti-PD-1 or anti-PD-L1 antibodies. TrialSite News includes Judge Saris’ ruling below:

The Court enters judgment in favor of Dana-Farber. Dana-Farber shall submit a form of judgement written ten days ordering correction of the patents.

What happened?

Dana-Farber won a major victory as the federal court ruled that one of the researchers should be listed as an inventor on six patents believed to be worth billions of dollars.  Connected to immunotherapy drugs, the patents represent a powerful new type of cancer treatment that unleashes a patient’s own immune system against cancer.  It is a total win for Dana-Faber; however given the stakes involved, more than likely Bristol-Myers Squbb.


Pin It on Pinterest